STAT
JULY 18, 2023
WASHINGTON — Medicare has a new proposal to pay hospitals more to stockpile essential drugs — an idea that comes as doctors report running low on critical chemotherapies and other drugs. But Medicare has its own new idea: paying hospitals to create a “buffer stock” of 86 medicines that HHS deems critical.
pharmaphorum
JANUARY 11, 2022
A prescription digital therapeutic (DTx) for leukaemia patients developed by Blue Note Therapeutics has been awarded breakthrough device status by the FDA. Last year, Biofourmis said its heart failure tool BiovitalsHF was the first DTx to be awarded breakthrough status by the FDA.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Hospital Pharmacy Europe
SEPTEMBER 1, 2023
However, where patients are receiving intravenous chemotherapy in combination with atezolizumab, they may remain on the transfusion. Evaluations by the US Food and Drug Administration (FDA) and other health authorities globally are also ongoing.
pharmaphorum
NOVEMBER 28, 2021
The three-year phase 2 trial will be carried out by researchers at Leeds University led by professor of clinical oncology and neuro-oncology Susan Short, and see if adding Sativex (nabiximols) to standard chemotherapy for recurrent glioblastoma can extend survival. Jazz acquired rights to Sativex when it completed its $7.2
pharmaphorum
JULY 6, 2022
The FDA has granted a priority review to Roche’s T-cell engager Lunsumio as a treatment for follicular lymphoma (FL), setting up a decision on the drug by 29 December. The post FDA to decide on Roche’s lymphoma drug Lunsumio before year-end appeared first on.
European Pharmaceutical Review
APRIL 30, 2024
Last week, the US FDA approved a new gene therapy for eligible adults with haemophilia B. If approved, fruquintinib could provide a new oral, chemotherapy-free option as the first and only selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR) receptors approved in the EU for this disease, according to Takeda.
Hospital Pharmacy Europe
AUGUST 23, 2023
Targeting CD40 with mitazalimab has the potential to augment responses to chemotherapy. The EMA orphan drug designation follows a similar approval by the FDA in May 2023. The post EMA grants mitazalimab orphan drug designation for pancreatic cancer appeared first on Hospital Pharmacy Europe. A median duration of response of 8.7
Expert insights. Personalized for you.
78 
Let's personalize your content